
President & CEO @AcadForPatients, former Editor @BioCentury. Preparing patients to contribute their expertise to drug development, regulation, access. She/her.
Joined September 2015
- Tweets1.7K
- Following905
- Followers1.3K
- Likes1.2K
Pinned Tweet
Exciting news from @AcadForPatients: The Patients' Academy for Research Advocacy is now a 501(c)(3) nonprofit!
Thrilled to announce that The Patients' Academy for Research Advocacy has been granted 501(c)(3) status. We are so excited to get to work for patients and care partners. Learn about our mission and approach at patients-academy.org.
Attention # nonprofit health leaders! Apply to @fastercures' LeadersLink mentor program for nonprofit leaders involved in biomed R&D. Learn more and apply here: bit.ly/2MUH2u5
Good evening Patient Advocacy Twitter! What role do you all think research advocates should have in helping to improve diversity/representation in clinical trials?
I’m interested in your thoughts about how individual advocates as well as PAOs can help.
Susan Schaeffer retweeted
barbie’s wheelchair vs my actual wheelchair: a critical comparison
aka the best twitter thread i will ever post
strap in
#Barbie
Got a delivery today from one of the major carriers, and the driver was so wonderful I wanted to leave feedback online.
After the first question, the system displayed a prompt to double check that I really meant to give a 5 out of 5.
Mustn’t happen very often 🤣
This cannot be right. My Vocabulary Size is about: 【30652】! What about you? arealme.com/vocabulary-size-… #EnglishVocabularySizeTest
Attn @jeff_cranmer
Susan Schaeffer retweeted
“If courts can overturn drug approvals without regard for science or evidence,” the letter said, “or for the complexity required to fully vet the safety and efficacy of new drugs, any medicine is at risk for the same outcome as mifepristone.”
Breaking News: Executives from over 250 drug companies called for the reversal of a judge’s abortion drug ruling, warning it could disrupt the entire industry. nyti.ms/41ilSJW















